Integrating the “immunome” in the stratification of myelodysplastic syndromes and future clinical trial design
S Winter, S Shoaie, S Kordasti… - Journal of Clinical …, 2020 - ascopubs.org
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and often
include a dysregulation and dysfunction of the immune system. In the context of population …
include a dysregulation and dysfunction of the immune system. In the context of population …
[HTML][HTML] Refractory Anemia with Ring Sideroblasts (RARS) and RARS with Thrombocytosis (RARS-T)–“2019 Update on Diagnosis, Risk-stratification, and …
MM Patnaik, A Tefferi - American journal of hematology, 2019 - ncbi.nlm.nih.gov
Abstract Disease Overview: Ring sideroblasts (RS) are erythroid precursors with abnormal
perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the …
perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the …
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
F Forghieri, V Nasillo, A Paolini, F Bettelli… - International Journal of …, 2020 - mdpi.com
Nucleophosmin (NPM1) gene mutations rarely occur in non-acute myeloid neoplasms
(MNs) with< 20% blasts. Among nearly 10,000 patients investigated so far, molecular …
(MNs) with< 20% blasts. Among nearly 10,000 patients investigated so far, molecular …
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
Myeloid neoplasms are clonal hematopoietic stem cell disorders driven by the sequential
acquisition of recurrent genetic lesions. Truncating mutations in the chromatin remodeler …
acquisition of recurrent genetic lesions. Truncating mutations in the chromatin remodeler …
SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process
M Jiang, M Chen, Q Liu, Z Jin, X Yang… - Frontiers in …, 2023 - frontiersin.org
Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by
ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by …
ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by …
[HTML][HTML] Calling variants in the clinic: informed variant calling decisions based on biological, clinical, and laboratory variables
ZS Bohannan, A Mitrofanova - Computational and structural biotechnology …, 2019 - Elsevier
Deep sequencing genomic analysis is becoming increasingly common in clinical research
and practice, enabling accurate identification of diagnostic, prognostic, and predictive …
and practice, enabling accurate identification of diagnostic, prognostic, and predictive …
[HTML][HTML] Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs
P Wu, J Weng, M Li, Z Lu, C Deng, Q Sun… - American journal of …, 2019 - ncbi.nlm.nih.gov
The molecular determinants of the clinical response to Hypomethylating agents (HMAs) in
patients with myelodysplastic syndromes (MDS) are unclear. We analyzed 84 adult patients …
patients with myelodysplastic syndromes (MDS) are unclear. We analyzed 84 adult patients …
Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine
CL O'Connell, MR Baer, AD Ørskov, SK Saini… - Clinical Cancer …, 2022 - AACR
Purpose: We hypothesized that resistance to hypomethylating agents (HMA) among patients
with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) …
with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) …
Treatment of myelodysplastic syndrome in the era of next‐generation sequencing
M Tobiasson, AO Kittang - Journal of internal medicine, 2019 - Wiley Online Library
Next‐generation sequencing (NGS) is rapidly changing the clinical care of patients with
myelodysplastic syndrome (MDS). NGS can be used for various applications:(i) in the …
myelodysplastic syndrome (MDS). NGS can be used for various applications:(i) in the …
Luspatercept in myelodysplastic syndromes: who and when
RS Komrokji - Hematol Oncol Clin North Am, 2020 - books.google.com
Anemia is the hallmark of myelodysplastic syndromes (MDS), a group of neoplastic stem cell
diseases characterized clinically by bone marrow failure and the tendency to progress to …
diseases characterized clinically by bone marrow failure and the tendency to progress to …